Anosognosia in schizophrenia: hidden in plain sight.

Innov Clin Neurosci

Dr. Lehrer is from Wright State University Boonshoft School of Medicine, Department of Psychiatry, Dayton, Ohio, and Summit Behavioral Healthcare, Cincinnati, Ohio; Dr. Lorenz is from Wright State University Boonshoft School of Medicine, Department of Psychiatry, Dayton, Ohio, and USAF Medical Center, Wright-Patterson Air Force Base, Department of Mental Health, Ohio.

Published: May 2014

Objective: Poor insight is a cardinal symptom of schizophrenia that, while not universally and uniformly expressed in all patients, is among the most common of its manifestations. Available neurobiological and neurocognitive evidence linking the phenomenon to core pathophysiology of schizophrenia justifies extension of the anosognosia construct to schizophrenia-related insight deficits. Poor insight is a core attribute of schizophrenia, occurring in 57 to 98 percent of patients. Insight is an important outcome predictor, associated with treatment adherence, relapse frequency, symptom remission, psychosocial functioning, vocational attainment, and risk of violence toward self or others. Combined findings lend urgency to the importance of reducing psychotic relapse. This can only be achieved in the majority of patients with consistent medication adherence- something that is often exceedingly difficult in patients lacking belief in the fact of their illness. This article examines whether anosognosia, the unawareness of deficit or illness, should apply to our understanding of insight deficits in patients with schizophrenia. Although research in the field is limited at this time, there is hope that anosognosia as a symptom of schizophrenia will become a focus of further research and a critically important therapeutic target amenable to treatment.

Design: This article is a literature review and conceptualization.

Conclusion: Limited research in the field gives cause for hope that anosognosia as a symptom of schizophrenia will become a critically important therapeutic target that is amendable to treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140620PMC

Publication Analysis

Top Keywords

symptom schizophrenia
12
poor insight
8
insight deficits
8
hope anosognosia
8
anosognosia symptom
8
schizophrenia will
8
critically therapeutic
8
therapeutic target
8
schizophrenia
6
anosognosia
5

Similar Publications

Background: Although schizophrenia and autism spectrum disorder (ASD) are currently conceptualized as distinct disorders, the similarity in their symptoms often makes differential diagnosis difficult. This study aimed to identify similarities and differences in the symptoms of schizophrenia and ASD to establish a more useful and objective differential diagnostic method and to identify ASD traits in participants with schizophrenia.

Methods: A total of 40 participants with schizophrenia (13 females, mean age: 34 ± 11 years) and 50 participants with ASD (15 females, mean age: 34 ± 8 years) were evaluated using the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) and other clinical measures.

View Article and Find Full Text PDF

Since its first inception by Kahlbaum in relation to schizophrenia, Catatonia syndrome is currently believed to cut across many neuropsychiatric diagnoses. In this focussed review, authors touch briefly on prevalence of catatonia in psychiatric presentations, discuss clinical diagnosis, neurobiology, typology, and conclude with a psychopharmacological algorithm to treatment.

View Article and Find Full Text PDF

Long-term effects of antipsychotics on serum BDNF levels in patients with schizophrenia.

Prog Neuropsychopharmacol Biol Psychiatry

December 2024

Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia; University of Applied Sciences Hrvatsko Zagorje Krapina, Krapina, Croatia. Electronic address:

Brain-derived neurotrophic factor (BDNF) is implicated in the etiology of schizophrenia, and peripheral BDNF levels are affected by the short-term antipsychotic treatment. However, the data on their long-term effects on BDNF levels are scarce, and there is no information whether BDNF levels change during sustained remission in relation to values in healthy individuals. The aim of the present study was to compare serum BDNF levels in patients in long-term remission and healthy controls.

View Article and Find Full Text PDF

Development and validation of a schizophrenia literacy scale for individuals diagnosed with schizophrenia.

Psychiatry Res

December 2024

School of Nursing, College of Medicine, Chang Gung University, Tao-Yuan City, Taiwan; Department of Nursing, Chang Gung University of Science and Technology, Tao-Yuan City, Taiwan; Department of Psychiatry, Chang Gung Memorial Hospital, Keelung Branch, Keelung City, Taiwan. Electronic address:

Schizophrenia literacy is key to early identification of schizophrenia and diminishment of stigma. This facilitates help-seeking and adherence to mental health treatment for individuals suffering from schizophrenia. However, validated measures assessing schizophrenia literacy among individuals diagnosed with schizophrenia remain limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!